Accelerating drug discovery from bed to benchside - Healthskouts

Silicon Valley giant NVIDIA is teaming up with pharma company AstraZeneca and the University of Florida on new artificial intelligence research projects aimed at boosting drug discovery and patient care. April 21, NVIDIA and AstraZeneca revealed a new drug-discovery model called MegaMoIBART, which is aimed at "reaction prediction, molecular optimization and de novo molecular generation." MegaMoIBART will be deployable on NVIDIA's platform for computational drug discovery, known as Clara Discovery, and will use a new kind of technology called transformer neural networks. This is the new breed of press releases flooding the domain of drug discovery, until recently the field of pure pharma & life sciences companies, medical chemistry procedures and very time-consuming biologic research. I used to discover and develop novel candidate drugs myself.